tiprankstipranks
Agilent Technologies (A)
NYSE:A
US Market
A
Agilent
RESEARCH TOOLSreports
Want to see A full AI Analyst Report?

Agilent (A) Stock Forecast & Price Target

3,357 Followers
See the Price Targets and Ratings of:

A Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Agilent
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

A Stock 12 Month Forecast

Average Price Target

$157.62
▲(29.33% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Agilent in the last 3 months. The average price target is $157.62 with a high forecast of $185.00 and a low forecast of $140.00. The average price target represents a 29.33% change from the last price of $121.87.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"104":"$104","145":"$145","186":"$186","124.5":"$124.5","165.5":"$165.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$185.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":157.6153846153846,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$157.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$140.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[104,124.5,145,165.5,186],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.52,119.94153846153846,125.36307692307692,130.7846153846154,136.20615384615385,141.6276923076923,147.04923076923077,152.47076923076924,157.8923076923077,163.31384615384616,168.73538461538462,174.15692307692308,179.57846153846154,{"y":185,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.52,117.83502958579881,121.15005917159763,124.46508875739644,127.78011834319526,131.0951479289941,134.4101775147929,137.72520710059172,141.04023668639053,144.35526627218934,147.67029585798815,150.98532544378696,154.3003550295858,{"y":157.6153846153846,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.52,116.47999999999999,118.44,120.39999999999999,122.36,124.32,126.28,128.24,130.2,132.16,134.12,136.08,138.04,{"y":140,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":105.593,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.145,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.813,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.899,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.017,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.766,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.491,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.518,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.081,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.54,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.52,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$185.00Average Price Target$157.62Lowest Price Target$140.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on A
Brandon Couillard
Wells Fargo
Wells Fargo
$165→$160
Buy
31.29%
Upside
Reiterated
05/28/26
Agilent price target lowered to $160 from $165 at Wells FargoAgilent price target lowered to $160 from $165 at Wells Fargo
Bank of America Securities Analyst forecast on A
Michael Ryskin
Bank of America Securities
Bank of America Securities
$150→$145
Buy
18.98%
Upside
Upgraded
05/28/26
Agilent upgraded to Buy from Neutral at BofAAgilent upgraded to Buy from Neutral at BofA
Stifel Nicolaus Analyst forecast on A
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$170
Buy
39.49%
Upside
Reiterated
05/28/26
Analysts Offer Insights on Healthcare Companies: Quanterix (NASDAQ: QTRX), Bio-Techne (NASDAQ: TECH) and Agilent (NYSE: A)
Morgan Stanley Analyst forecast on A
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$160
Buy
31.29%
Upside
Reiterated
05/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Barclays Analyst forecast on A
Luke Sergott
Barclays
Barclays
$140→$145
Buy
18.98%
Upside
Reiterated
05/28/26
Barclays Keeps Their Buy Rating on Agilent (A)
TD Cowen Analyst forecast on A
Daniel Brennan
TD Cowen
TD Cowen
$157→$155
Buy
27.18%
Upside
Reiterated
05/27/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phreesia (NYSE: PHR), Agilent (NYSE: A) and Pfizer (NYSE: PFE)
J.P. Morgan Analyst forecast on A
Casey Woodring
J.P. Morgan
J.P. Morgan
$180
Buy
47.70%
Upside
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A), Apogee Therapeutics (NASDAQ: APGE) and Pfizer (NYSE: PFE)
Goldman Sachs Analyst forecast on A
Evie Koslosky
Goldman Sachs
Goldman Sachs
$150→$155
Buy
27.18%
Upside
Reiterated
05/27/26
Goldman Sachs Reaffirms Their Buy Rating on Agilent (A)
RBC Capital Analyst forecast on A
Dan Leonard
RBC Capital
RBC Capital
$153
Buy
25.54%
Upside
Initiated
05/26/26
Agilent initiated with an Outperform at RBC CapitalAgilent initiated with an Outperform at RBC Capital
Robert W. Baird Analyst forecast on A
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$155→$156
Buy
28.01%
Upside
Reiterated
05/26/26
Agilent price target raised to $156 from $155 at BairdAgilent price target raised to $156 from $155 at Baird
Evercore ISI Analyst forecast on A
Vijay Kumar
Evercore ISI
Evercore ISI
$160→$140
Buy
14.88%
Upside
Assigned
04/06/26
Agilent price target lowered to $140 from $160 at Evercore ISIAgilent price target lowered to $140 from $160 at Evercore ISI
Nephron Analyst forecast on A
Jack Meehan
Nephron
Nephron
$145
Buy
18.98%
Upside
Upgraded
03/26/26
Agilent upgraded to Buy from Hold at Nephron ResearchAgilent upgraded to Buy from Hold at Nephron Research
Citi Analyst forecast on A
Patrick B Donnelly
Citi
Citi
$185
Buy
51.80%
Upside
Reiterated
03/11/26
Analysts Offer Insights on Healthcare Companies: Healthequity (NASDAQ: HQY), Apyx Medical (NASDAQ: APYX) and Agilent (NYSE: A)
HSBC Analyst forecast on A
Sidharth Sahoo
HSBC
HSBC
$180
Buy
47.70%
Upside
Initiated
01/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (NYSE: A), DENTSPLY SIRONA (NASDAQ: XRAY) and Exact Sciences (NASDAQ: EXAS)
Jefferies Analyst forecast on A
Tycho Peterson
Jefferies
Jefferies
$130
Hold
6.67%
Upside
Reiterated
10/17/25
Agilent (A) Gets a Hold from Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on A
Brandon Couillard
Wells Fargo
Wells Fargo
$165→$160
Buy
31.29%
Upside
Reiterated
05/28/26
Agilent price target lowered to $160 from $165 at Wells FargoAgilent price target lowered to $160 from $165 at Wells Fargo
Bank of America Securities Analyst forecast on A
Michael Ryskin
Bank of America Securities
Bank of America Securities
$150→$145
Buy
18.98%
Upside
Upgraded
05/28/26
Agilent upgraded to Buy from Neutral at BofAAgilent upgraded to Buy from Neutral at BofA
Stifel Nicolaus Analyst forecast on A
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$170
Buy
39.49%
Upside
Reiterated
05/28/26
Analysts Offer Insights on Healthcare Companies: Quanterix (NASDAQ: QTRX), Bio-Techne (NASDAQ: TECH) and Agilent (NYSE: A)
Morgan Stanley Analyst forecast on A
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$160
Buy
31.29%
Upside
Reiterated
05/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Barclays Analyst forecast on A
Luke Sergott
Barclays
Barclays
$140→$145
Buy
18.98%
Upside
Reiterated
05/28/26
Barclays Keeps Their Buy Rating on Agilent (A)
TD Cowen Analyst forecast on A
Daniel Brennan
TD Cowen
TD Cowen
$157→$155
Buy
27.18%
Upside
Reiterated
05/27/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phreesia (NYSE: PHR), Agilent (NYSE: A) and Pfizer (NYSE: PFE)
J.P. Morgan Analyst forecast on A
Casey Woodring
J.P. Morgan
J.P. Morgan
$180
Buy
47.70%
Upside
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A), Apogee Therapeutics (NASDAQ: APGE) and Pfizer (NYSE: PFE)
Goldman Sachs Analyst forecast on A
Evie Koslosky
Goldman Sachs
Goldman Sachs
$150→$155
Buy
27.18%
Upside
Reiterated
05/27/26
Goldman Sachs Reaffirms Their Buy Rating on Agilent (A)
RBC Capital Analyst forecast on A
Dan Leonard
RBC Capital
RBC Capital
$153
Buy
25.54%
Upside
Initiated
05/26/26
Agilent initiated with an Outperform at RBC CapitalAgilent initiated with an Outperform at RBC Capital
Robert W. Baird Analyst forecast on A
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$155→$156
Buy
28.01%
Upside
Reiterated
05/26/26
Agilent price target raised to $156 from $155 at BairdAgilent price target raised to $156 from $155 at Baird
Evercore ISI Analyst forecast on A
Vijay Kumar
Evercore ISI
Evercore ISI
$160→$140
Buy
14.88%
Upside
Assigned
04/06/26
Agilent price target lowered to $140 from $160 at Evercore ISIAgilent price target lowered to $140 from $160 at Evercore ISI
Nephron Analyst forecast on A
Jack Meehan
Nephron
Nephron
$145
Buy
18.98%
Upside
Upgraded
03/26/26
Agilent upgraded to Buy from Hold at Nephron ResearchAgilent upgraded to Buy from Hold at Nephron Research
Citi Analyst forecast on A
Patrick B Donnelly
Citi
Citi
$185
Buy
51.80%
Upside
Reiterated
03/11/26
Analysts Offer Insights on Healthcare Companies: Healthequity (NASDAQ: HQY), Apyx Medical (NASDAQ: APYX) and Agilent (NYSE: A)
HSBC Analyst forecast on A
Sidharth Sahoo
HSBC
HSBC
$180
Buy
47.70%
Upside
Initiated
01/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (NYSE: A), DENTSPLY SIRONA (NASDAQ: XRAY) and Exact Sciences (NASDAQ: EXAS)
Jefferies Analyst forecast on A
Tycho Peterson
Jefferies
Jefferies
$130
Hold
6.67%
Upside
Reiterated
10/17/25
Agilent (A) Gets a Hold from Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agilent

3 Months
Dan LeonardRBC Capital
Success Rate
18/26 ratings generated profit
69%
Average Return
+4.95%
Copying Dan Leonard's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +4.95% per trade.
1 Year
Brandon CouillardWells Fargo
Success Rate
32/42 ratings generated profit
76%
Average Return
+16.98%
Copying Brandon Couillard's trades and holding each position for 1 Year would result in 76.19% of your transactions generating a profit, with an average return of +16.98% per trade.
2 Years
Catherine Ramsey SchulteRobert W. Baird
Success Rate
32/44 ratings generated profit
73%
Average Return
+18.40%
Copying Catherine Ramsey Schulte's trades and holding each position for 2 Years would result in 72.73% of your transactions generating a profit, with an average return of +18.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

A Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
1
2
2
2
Buy
15
19
18
16
15
Hold
3
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
21
21
19
17
In the current month, A has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. A average Analyst price target in the past 3 months is 157.62.
Each month's total comprises the sum of three months' worth of ratings.

A Financial Forecast

A Earnings Forecast

Next quarter’s earnings estimate for A is $1.49 with a range of $1.48 to $1.51. The previous quarter’s EPS was $1.49. A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year A has Performed in-line its overall industry.
Next quarter’s earnings estimate for A is $1.49 with a range of $1.48 to $1.51. The previous quarter’s EPS was $1.49. A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year A has Performed in-line its overall industry.

A Sales Forecast

Next quarter’s sales forecast for A is $1.84B with a range of $1.83B to $1.85B. The previous quarter’s sales results were $1.83B. A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year A has Performed in-line its overall industry.
Next quarter’s sales forecast for A is $1.84B with a range of $1.83B to $1.85B. The previous quarter’s sales results were $1.83B. A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year A has Performed in-line its overall industry.

A Stock Forecast FAQ

What is A’s average 12-month price target, according to analysts?
Based on analyst ratings, Agilent Technologies’s 12-month average price target is 157.62.
    What is A’s upside potential, based on the analysts’ average price target?
    Agilent Technologies has 29.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is A a Buy, Sell or Hold?
          Agilent Technologies has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Agilent Technologies’s price target?
            The average price target for Agilent Technologies is 157.62. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $185.00 ,the lowest forecast is $140.00. The average price target represents 29.33% Increase from the current price of $121.87.
              What do analysts say about Agilent Technologies?
              Agilent Technologies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of A?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.